Children are less likely to have priority in getting vaccinated against COVID-19, Lee Ping-ing (李秉穎), a member of the Central Epidemic Command Center’s (CECC) specialist advisory panel, said yesterday.
Lee, a physician in National Taiwan University Hospital’s division of pediatric infectious diseases, made the remark on the sidelines of a conference on the effects of COVID-19 on children’s health in Taipei.
Clinical trials of COVID-19 vaccine candidates have not included children, he said, adding that statistical data suggests that children do not have a higher risk of infection and that the risks of them developing serious complications or dying are also relatively low.
When effective vaccines become available in Taiwan, children are unlikely to be at the front of the vaccination line, Lee said.
Three types of vaccine candidates have progressed faster: messenger RNA (mRNA) vaccines, vaccines based on adenoviral vectors and vaccines based on recombinant proteins, he said.
The mRNA vaccines are easier and faster to mass produce, but they present higher risks of systemic or local adverse events, and require ultra-low temperatures for storage and transport, Lee said.
The vaccines based on adenoviral vectors are considered relatively safe, but they have not been widely administered as a commercial vaccine, he said, adding that the vaccine might be less effective in people who already have antibodies that neutralize adenoviruses, and it is not suitable for people with weakened immune systems.
The recombinant-protein-based vaccines are thought to be the safest and most efficient, but they are more difficult to produce quickly, Lee said.
On Friday, Centers for Disease Control Deputy Director-General Chuang Jen-hsiang (莊人祥), the CECC’s spokesperson, said that Taiwan can buy the vaccine that Oxford University is developing with British drugmaker AstraZeneca through the COVAX allocation platform.
Foreign media have reported that the vaccine shows an “encouraging” immune response in older adults, and that 99 percent of those given the vaccine in a mid-term clinical trial developed antibodies.
Asked if Taiwan can buy the vaccine, Chuang said that the center has started negotiations to acquire it in August and September next year, but he declined to provide further details.
Taiwan can buy the vaccine through COVAX, he said, adding that the government has also contacted the manufacturer regarding issues such as quantity and timing.
The Oxford-AstraZeneca vaccine is expected to be cheaper than the one developed by Pfizer in collaboration with BioNTech, and easier to ship, as it can be stored at 2°C to 8°C, Chuang said.
The Pfizer vaccine, an mRNA vaccine, must be stored at ultra-low temperatures — as low as minus-80°C.
The CECC has budgeted NT$11.5 billion (US$399.03 million) for the purchase of 30 million doses of a COVID-19 vaccine, which would be enough to vaccinate 15 million people, Chuang said.
While the antiparasitic drug ivermectin is being touted as a treatment for COVID-19 in many parts of the world, Taiwanese experts on Monday warned against regular use of the drug in COVID-19 treatment, citing a lack of solid evidence. “Following an experts’ meeting, we do not recommend regular use of ivermectin in treating COVID-19 due to the lack of enough evidence,” said Chang Shan-chwen (張上淳), convener of the Central Epidemic Command Center’s (CECC) expert advisory panel. A report in the American Journal of Therapeutics said that meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 patients had found large,
CLASSES HALTED: Cram schools have had to return tuition fees due to mandatory closures and might need to lay off half of their staff because of a lack of revenue The COVID-19 pandemic has taken a toll on the education sector, with some cram schools and tutoring centers saying they might soon be unable to pay their instructors due to the extension of a nationwide level 3 COVID-19 alert. The heightened alert level means schools must remain closed, so cram schools and tutoring centers have had to return tuition fees, one cram school said. June is normally the peak season for recruiting new students at cram schools and tutoring centers, but this year many such schools might need to lay off half of their staff due to a lack of
A person who was on Friday reported as the first in Taiwan to die after receiving a COVID-19 vaccine died of a heart attack, a Central Epidemic Command Center (CECC) official said yesterday. The deceased, whose sex and age were not disclosed, had coronary artery disease, which led to a fatal heart attack, Centers for Disease Control Deputy Director-General Chuang Jen-hsiang (莊人祥), who is the CECC’s spokesman, told a news conference, citing the autopsy report. It was the first death listed as a possible adverse event after receiving the AstraZenenca COVID-19 vaccine since the start of the vaccination program on March 22. The
Taichung, Kaohsiung and Chiayi County are to adopt a COVID-19 vaccine administration method invented in a town in Japan to make the inoculation process easier for elderly people, the local governments said. Under the method, dubbed the “Umi-machi style,” seniors who go to get their jabs at designated venues remain seated while a team of medical staff move from one person to another to administer their shots. Umi, a town in Fukuoka Prefecture, conceived of the idea by observing Toyota’s vehicle assembly lines, which are renowned for being efficient. Taichung, which has about 36,000 people older than 85, would try to